Ginseng is one of the most commonly used herbal medicines and health foods. Korean red ginseng (KRG; Panax ginseng C.A. Meyer) extract is known to have potential therapeutic activities, such as anti-viral effects, the amelioration of food allergies, anti-oxidant effects, and obesity reduction. Nevertheless, no reports have been issued the modulatory effects of KRG extract on the activity of cytochrome P450 (CYP). In the present study, we investigated the modulatory effect of KRG extract in vitro and in vivo by using pooled human liver microsomes and male ICR mice. When human liver microsomes were incubated with KRG extract at 0.01-10 mg/ml, CYP1A2, 2B6, 2C19, 2D6, and 3A were not significantly inhibited by KRG extract, although CYP2B6 was slightly inhibited. Mice were orally administered KRG extract at 50, 250, or 500 mg/kg daily for 3, 7, or 14 days. However, the activities of CYPs in mouse livers were not significantly different from those of vehicle-treated controls. In conclusion, no significant ginseng-drug interaction was observed. KRG extract did not significantly modulate the activities of CYPs in vitro or in vivo.
Introduction
Ginseng is one of the most popular used herbal medicines worldwide. Generally, ginseng itself or natural medicines containing ginseng components are believed to have various therapeutic effects, such as, tonic, immune system enhancement, and physical stamina and appetite stimulating effects.
Korean red ginseng (KRG) extract are prepared by steaming and drying fresh ginseng. During this process, the chemical constituents may be transformed, and this is of pharmacologic importance. Recently KRG extract have been reported to have various pharmacological effects, such as, anti-viral, food allergy preventing, anti-oxidant, and anti-obesitic effects [7, 9, 15, 16] . Furthermore, KRG extract has been reported to be an effective remedy for influenza-like illnesses and atopic dermatitis [3, 14] .
Although the co-administration of drugs with KRG extract may give rise to ginseng-drug interactions, ginseng-drug interactions have not been tested. In herbal medicine, herb-drug interactions are an important research consideration. Of the many reasons for herb-drug interactions, the most important is herb-drug interactions originating from cytochrome P450s (CYPs). The inhibition or induction of the activities of CYPs can lead to pharmacokinetic drug interactions. Representatively, bergamottin in grapefruit juice strongly inhibits CYP3A activity in intestine and liver [13] and hyperforin in St. John's wort extract significantly induces CYP3A in liver [12] .
In previous reports, the modulatory effects of ginseng extract or components on CYP activities were investigated in vitro. For example, it has been reported that ginsenoside Rd weakly inhibits activities of CYP3A and 2D6 in cDNA expressed CYP enzyme and that standardized ginseng extract reduce the effects of CYP1 family on the activities of human recombinant CYP1A1, 1A2, and 1B1 [2, 6] . In one study, eight ginsenosides and their aglycones were found to potently induce CYP1A1 expression, and furthermore, ginsenoside Rf showed a weak effect on CYP3A promoter activation in HepG2 cells [5, 10] .
Although the regulatory effects of ginseng extract or active components on the activities of CYPs in vitro have been reported, no investigation has been conducted on the modulatory effects of KRG extract in vitro and in vivo. Moreover, the modulatory effects of KRG extract on metabolic enzymes after orally administration to animals or man have not been studied. In the present study, we investigated the modulatory effect of KRG extract in vitro and in vivo using pooled human liver microsomes (HLMs) and male ICR mice in order to study the potential herb-drug interaction. Using cocktail probes for CYP1A, 2B, 2C, 2D, 2E and 3A, the activities of the six major CYPs involved in drug metabolism in human were evaluated after incubating pooled HLMs with KRG extract and in microsomal protein from mice treated with KRG extract orally.
Materials and Methods
Reagents and Samples Animal treatment and preparation of liver S9 fractions Specific pathogen-free male ICR mice were obtained from Orient Bio Inc., (Seongnam, Korea). Animals were received at 4 weeks old and acclimated for at least 2 weeks. Animal quarters were strictly maintained at 23±3 o C and 40-60% relative humidity. A 12 hr light/dark cycle was used at an intensity of 150-300 Lux. KRG extract in distilled water at 50, 250, or 500 mg/kg was treated to mice orally for 3, 7, or 14 consecutive days. Twenty-four hours after last dosing, all animals were subjected to necropsy. Livers were removed and homogenized with four volumes of ice-cold 0.1 M potassium phosphate buffer (pH 7.4). The liver S9 fractions isolated by differential centrifugation at 9,000 g were stored at -80°C until required. Protein contents were determined using bovine serum albumin as a standard, as previously described [11] . All animal care and procedures were con- Monooxygenase activities in mice treated with KRG extract Liver S9 fractions were incubated with cocktail probes with 6 types of CYP substrates, and NGS in 0.1 M potassium phosphate buffer (pH 7.4). After incubation for 60 min at 37°C, the reaction was stopped by adding 100 μl acetonitrile with 0.1% formic acid containing an internal standard solution (10 μg/ml terfenadine in methanol). Sample were mixed and centrifuged at 16,000 g for 5 min, and 10 μl aliquots were analyzed by LC/MS/MS.
Hepatotoxicity Parameters
Liver homogenate protein levels were determined as described by Lowry et al. (1951) [11] , using bovine serum albumin as a standard. Lipid peroxides were determined by thiobarbituric acid reaction, as previously described [13] , and liver GSH levels were determined using Ellman's method [1] .
Instrumentation
The activities of CYP in incubated samples were determined using an AccelaTM LC system coupled to a TSQ Vantage triple quadrupole mass spectrometer (Thermo Fisher Scientific Inc., USA) equipped with a HESI-II Spray source. Samples (20 μl) were injected into a chromatographic system and separated on an Inertsil® ODS-3 column, 5 μm 
Results
Inhibitory effects of KRG extract on monooxygenase activities in pooled human liver microsomes To study the potential inhibitory effects of KRG extract on individual CYP enzymes, probe reaction assays were conducted using cocktail for CYP1A2, 2B6, 2C19, 2D6, 2E1 and 3A, which are the major CYP family members involved in human drug metabolism (Fig. 1) . As shown in Table 1 values were determined for each CYP, and these were used to estimate inhibitory potencies. Although incubation with 0.01-10 mg/ml of extract for 60 min slightly inhibited CYP2B6-catalyzed bupropion 1'-hydroxylation with an IC50 at 13.7 mg/ml, other CYPs were not significantly inhibited Male ICR were treated orally with 50, 250, or 500 mg/kg of KRG extract daily for 3 days, respectively. Animals were subjected to necropsy 24 hours after last treatments. Values are means±SEs for five animals. VH, vehicle treated animals. by KRG extract.
Hepatotoxicity of KRG extract
To investigate the toxic effects of KRG extract, changes in liver weights and GSH and malondialdehyde contents were determined after daily treatment for 3, 7, or 14 days with 0, 50, 250 or 500 mg/kg of extract daily. As shown in Table 2 , the liver weights were not changed, and GSH and malondialdehyde contents were not decreased by treatment for 14 days daily dose (Fig. 2) . Additionally, we determined the activities of serum ALT and AST in animals orally treated with extract for 3, 7, or 14 days. No significant hepatotoxicity was observed versus vehicle treated controls (data not shown).
Modulatory effects of KRG extract on monooxygenase activities in mouse liver
To investigate ginseng-drug interactions in vivo, mice To evaluate the modulatory effects of KRG extract, we tested their inhibitory effects on 6 types of CYP using HLMs in vitro. In previous studies, the ginsenosides Rb1, Rb2, Rc, Rd, Re, Rf and Rg1 were found to inhibit the catalytic activities of CYP1A1, CYP1A2 and CYP1B1 at a concentration of 50 μg/ml in human recombinant CYPs [2] , but the modulatory effects of KRG extract on CYP activities were not investigated in HLMs. In the present study, we tested the modulatory effects of KRG extract instead of single KRG components in HLMs, because it was difficult to real reactions between ginsenoside components and specific CYPs under biologic conditions. For the in vivo study, we orally administrated KRG extract to mice daily for 3, 7, or 14 days at dosages of 50, 250, or 500 mg/kg; the daily recommended dose in man is 50 mg/kg. In the present study, we orally treated mice at 10 times these recommended dosages. Nevertheless, CYP activities in mouse liver showed no notable changes.
The major pharmacological components of ginseng are ginsenosides and their aglycones, which are known to have modulatory effects on the activities of CYPs. Thus, the quantities of these principals in extract and their bioavailabilities are likely to influence ginseng-drug interactions [2, 6] . The 14 ginsenosides (Rg1, Re, Rf, Rh1, Rg2, Rb1, Rc, Rb2, Rb3, Rd, Rg3, Rk1, Rg5, and Rh2) in KRG extract were present at 66 to 76 mg/g of extract [8] . Furthermore, ginsenosides have very low oral bioavailabilities. For example, the bioavailability of the major ginsenoside Rb1 P.O. is only 4.35% when Panax notoginsengs saponins (PNS) are administered at 600 mg/kg to rats [18] , and the bioavailability of Rg1 is only 3.29% at a dose of 1,500 mg/kg P.O. of PNS in rat [4] . Moreover, the absolute bioavailability of Rd in dogs is only 0.26%, though Rd has an inhibitory effect on CYP3A and 2D6 in vitro [17] . Therefore, although ginsenosides and ginseng extract modulate CYP activity in vitro, no modulatory effects was observed in vivo due to the low oral bioavailabilities of ginsenosides.
In conclusion, KRG extract were not found to modulate the activities of CYPs, which suggests that KRG extract exhibit no significant pharmacokinetic herb-drug interactions with prescribed drugs metabolized by the six major CYP families. However, further human pharmacokinetics studies should be conducted to confirm the safety of KRG extract in those that take it regularly for long periods of time.
